ALTSTATION.IO

Medtronic plc (MDT) Stock Analysis

By Nova Skye | AltStation.io | Updated October 12, 2026

Price

$88.14

Change

+0.44%

Market Cap

$112.74B

Avg Volume

13.1M

Company Overview

Medtronic is a medical device giant in the Healthcare sector, founded in 1949 and headquartered in Galway, Ireland. The company develops and sells therapeutic hardware and clinical software to healthcare systems, physicians, and patients across global markets. Its business is built on three core divisions: Cardiovascular, Neuroscience, and Medical Surgical. The catalog runs deep, selling everything from implantable pacemakers and aortic valves to spinal modulation implants, surgical staplers, and continuous glucose monitors.

Medtronic is an established market leader in medtech, not a challenger, backed by a massive footprint across hospitals worldwide. Its scale gives it a major distribution moat in cardiac rhythm management, spine therapies, and minimally invasive tools. However, focused competitors like Boston Scientific, Abbott Laboratories, and Stryker constantly threaten its market share in high-margin cardiology and orthopedic niches. Medtronic’s sheer size can slow its rollout speed, but its enterprise-level contracting power keeps hospital accounts locked down.

The company is currently in expansion mode, growing total revenue from $32.4 billion in fiscal 2024 with 5.2% organic growth up to $33.5 billion in 2025 and $36.4 billion in 2026. The Cardiovascular segment remains the primary engine, delivering $13.98 billion in 2026 revenue behind cardiac ablation, structural heart implants, and remote monitoring software. Medtronic is aggressively rolling out AI-driven surgical video platforms and next-generation cardiac therapies to defend its premium pricing. It is a disciplined growth story focused on optimizing higher-margin device categories rather than chasing speculative pivots.

Key Financials

Market Cap

$112.74B

Revenue

$37.54B

EBITDA

$10.41B

Gross Margin

65.3%

Profit Margin

13.9%

Revenue Growth

13.7%

Total Cash

$8.82B

Total Debt

$28.15B

Free Cash Flow

$5.41B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

21.66

Forward P/E

13.74

Beta

0.57

52-Week High

$106.33

52-Week Low

$73.31

EPS

$4.07

50-Day Avg

$90.05

200-Day Avg

$88.42

Price/Book

2.25

Technical Analysis

MDT trades at $88.14, 53% of the way from its $72.06 52-week low to its $102.92 high. The stock is 14.03% below that high and 22.78% above the low. Price sits 0.57% below the 20-day moving average of $88.99, while 20-day momentum is negative 1.93%. Five-day momentum has improved to 2.43%, pointing to a short-term rebound. Near-term support is $85.51, while resistance is $93.40.

Recent News and Developments

FDA clears Medtronic’s navigated ApexCut sinus-surgery blades

Medtronic received FDA 510(k) clearance for ApexCut EM blades that connect directly to its Stealth AXiS ENT navigation system. The company expects the first U.S. clinical cases later in 2026 after releasing updated navigation software. Source: Medtronic

Medtronic sets final MiniMed exchange ratio

Medtronic set the MiniMed split-off exchange ratio at 4.5939 MiniMed shares for each accepted Medtronic share. It offered up to 225,361,295 MiniMed shares and said it could add another 27,452,053 shares if the offer was oversubscribed. Source: Medtronic

Barclays starts Medtronic at Equalweight with a $95 target

Barclays initiated coverage of MDT with an Equalweight rating and a $95 price target on October 6. The call was cautious: MDT had closed the previous session at $87.97, leaving limited upside to the target. Source: StreetInsider

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is $37.54 billion and is growing 13.7%, giving the bull case a solid operating foundation. The FDA clearance for ApexCut EM blades adds another product catalyst, with the first U.S. clinical cases expected later in 2026. The blades connect directly to Medtronic’s Stealth AXiS ENT navigation system, strengthening the value of its existing platform. Wall Street’s consensus recommendation is buy across 25 analysts, with a $104.44 average target versus the current $88.14 price. BTIG also maintained its Buy rating with a $99 target on October 12. MDT offers credible growth, identifiable catalysts, and analyst-backed upside at a P/E of 21.66.

Bear Case

The balance sheet is the clearest weakness: total debt stands at $28.15 billion against $8.82 billion in cash. A P/E of 21.66 leaves room for disappointment if 13.7% revenue growth slows. The analyst target range runs from $85.00 to $121.00, showing meaningful disagreement about the stock’s value. Barclays started coverage at Equalweight with a $95 target on October 6, signaling a more restrained outlook than the consensus buy rating. BTIG also cut its target from $100 to $99, even though it kept its Buy rating. Technically, MDT remains 14.03% below its 52-week high and faces resistance at $93.40, so the stock has not established a clean breakout.

What to Watch

The first level to watch is $93.40, the 30-day high and near-term resistance. A drop through $85.51, the 30-day low, would weaken the rebound that produced 2.43% five-day momentum. Investors should also track whether MDT can reclaim its $88.99 20-day moving average and reverse its negative 1.93% 20-day momentum. The ApexCut rollout is a specific catalyst, with the first U.S. clinical cases expected later in 2026 after updated navigation software is released. The MiniMed split-off also matters: Medtronic set the final exchange ratio at 4.5939 MiniMed shares per accepted Medtronic share and offered up to 225,361,295 shares, with another 27,452,053 available if oversubscribed. Over the next quarter, the thesis improves if revenue growth holds near 13.7% and price clears $93.40; it weakens if growth slips or the stock breaks below $85.51.

Analyst Consensus

BUY

Based on 25 analyst opinions

Low Target

$85.00

Mean Target

$104.44

High Target

$121.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

95,000

Earnings & Dividends

Next Earnings

Nov 17, 2026

EPS (Trailing)

$4.07

Dividend Yield

328.0%

Payout Ratio

70.0%

Frequently Asked Questions

Is MDT a good stock to buy?

The consensus recommendation is buy based on 25 analysts, and revenue growth is 13.7%. The clear takeaway is that analysts are bullish, but investors still need to weigh the $28.15 billion debt load.

What is MDT’s price target?

The average analyst target is $104.44, with estimates ranging from $85.00 to $121.00. The takeaway is that the consensus target sits above the current $88.14 price, although analyst expectations vary widely.

What is MDT’s 52-week high and low?

The technical price series shows a 52-week high of $102.92 and a low of $72.06. At $88.14, MDT is 14.03% below the high and 22.78% above the low, placing it 53% of the way through that range.

What are MDT’s support and resistance levels?

Near-term support is the 30-day low of $85.51, while resistance is the 30-day high of $93.40. The takeaway is that these are the key levels framing MDT’s immediate trading range.

Is MDT stock overvalued?

MDT trades at a P/E of 21.66 with revenue growth of 13.7%. The data does not establish that the stock is overvalued, so the takeaway is that investors must decide whether the growth rate justifies the earnings multiple.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 12, 2026.